drugset / Trial / NCT06538480
Zopa Retreatment and Vector Shedding in Adults With RRP
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This open-label study evaluates safety, vector shedding, and retreatment efficacy of Zopapogene imadenovec (Zopa) in adults with recurrent respiratory papillomatosis (RRP). Two cohorts will be enrolled (n=30): Cohort 1 to assess the magnitude and duration of adenoviral vector shedding in urine, feces, skin, and nasal tissue; Cohort 2 to assess the complete response rate following retreatment.
Timeline
- Start
- 2024-07-11
- Primary completion
- 2027-12-02
- Completion
- 2028-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zopapogene imadenovec | Unknown | 5e+11 unknown | Subcutaneous |